Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04510129 · ClinicalTrials.gov registry record
A Multicenter Cancer Biospecimen Collection Study
A clinical trial of Cervical Cancer and Hepatocellular Carcinoma, sponsored by Cofactor Genomics.
- Recruiting
- Registry status
- 1,650
- Enrollment target
- 1
- Study location
NCT04510129 is a study of Cervical Cancer and Hepatocellular Carcinoma that is actively recruiting participants, run by Cofactor Genomics. The registered enrollment target is 1,650 participants, above the 559-participant average among 144 other Cervical Cancer trials with a reported enrollment target (195% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04510129, a study of Cervical Cancer and Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Cofactor Genomics.
- RECRUITING
- Registry status
- 1,650 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST OncoPrism™ assay
Study Locations (1)
California
- Curebase - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,650 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2027-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04510129
The ClinicalTrials.gov registry entry for NCT04510129 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,650 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 559-participant average among 144 other Cervical Cancer trials with a reported enrollment target (195% higher). The listed sponsor is Cofactor Genomics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which OncoPrism™ assay is the first listed.
NCT04510129 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04510129 about?
NCT04510129 is a clinical study titled "A Multicenter Cancer Biospecimen Collection Study". This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent stu...
What is the current status of trial NCT04510129?
This trial is currently recruiting. The enrollment target is 1,650 participants. The study started on 2020-02-05. Estimated completion is 2027-02.
What conditions does trial NCT04510129 study?
This clinical trial studies the following conditions: Cervical Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Urothelial Carcinoma.
What interventions are being tested in trial NCT04510129?
The interventions under investigation include: OncoPrism™ assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04510129?
This trial is sponsored by Cofactor Genomics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04510129 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy
RECRUITING
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
PopSci CHW4CervixHealth
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.